Utilize este identificador para referenciar este registo:
https://hdl.handle.net/1822/44342
Título: | Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data |
Autor(es): | Guinney, Justin Wang, Tao Laajala, Teemu D. Winner, Kimberly Kanigel Bare, J. Christopher Neto, Elias Chaibub Khan, Suleiman A. Peddinti, Gopal Airola, Antti Pahikkala, Tapio Mirtti, Tuomas Pathak, Swetabh Pattin, Alexandrina Ankerst, Donna P. Jian Peng Petersen, Anne H. Bot, Brian M. Philip, Robin Piccolo, Stephen R. Pölsterl, Sebastian Polewko-Klim, Aneta Azima, Helia Rao, Karthik Xiang Ren Rocha, Miguel Rudnicki, Witold R. Ryu, Hyunnam Scherb, Hagen Shen, Liji Sehgal, Raghav Seyednasrollah, Fatemeh Jingbo Shang Baertsch, Robert Bin Shao Sher, Howard Shiga, Motoki Sokolov, Artem Söllner, Julia F. Lei Song Stuart, Josh Abdallah, Kald Sun, Ren Sweeney, Christopher J. Ballester, Pedro J. Tahmasebi, Nazanin Kar-Tong Tan Tomaziu, Lisbeth Usset, Joseph Yeeleng S Vang Vega, Roberto Vieira, Vítor Wang, David Norman, Thea Difei Wang Bare, Chris Junmei Wang Lichao Wang Sheng Wang Yue Wang Wolfinger, Russ Chris Wong Zhenke Wu Jinfeng Xiao Xiaohui Xie Friend, Stephen Bhandari,Vinayak Doris Xin Hojin Yang Nancy Yu Xiang Yu Zahedi, Sulmaz Zanin, Massimiliano Chihao Zhang Jingwen Zhang Shihua Zhang Yanchun Zhang Dang,Cuong C. Stolovitzky, Gustavo Zhu, Hongtu Zhu, Shanfeng Zhu, Yuxin Soule, Howard Ryan, Charles J. Scher, Howard I. Sartor, Oliver Xie, Yang Aittokallio, Tero Dunbar, Maria Bekker-Nielsen Fang Liz Zhou Costello, James C. Anghel, Catalina Buchardt, Ann-Sophie Buturovic, Ljubomir Cao, Da Minseong Lim Chalise, Prabhakar Junwoo Cho Tzu-Ming Chu Coley, R. Yates Conjeti, Sailesh Correia, S. Dai, Ziwei Dai, Junqiang Dargatz, Philip Delavarkhan, Sam Henry Lin Deng, Detian Dhanik, Ankur Yu Du Elangovan, Aparna Ellis, Shellie Elo, Laura L. Espiritu, Shadrielle M. Fan, Fan Farshi, Ashkan B. Freitas, Ana Alão Xihui Lin Fridley, Brooke Fuchs, Christiane Gofer, Eyal Peddinti, Gopalacharyulu Graw, Stefan Greiner, Russ Yuanfang Guan Jing Guo Gupta, Pankaj Guyer, Anna I. Jing Lu Han, Jiawei Hansen, Niels R. Chang, Billy H. W. Hirvonen, Outi Huang, Barbara Chao Huang Jinseub Hwang Ibrahim, Joseph G. Jayaswal, Vivek Jeon, Jouhyun Mahmoudian, Mehrad Zhicheng Ji, Juvvadi, Deekshith Jyrkkiö, Sirkku Katouzian, Amin Kazanov, Marat D. Khayyer, Shahin Kim, Dalho Golinska, Agnieszka K. Koestler, Devin Pilatti, F. Manshaei, Roozbeh Kondofersky, Ivan Krautenbacher, Norbert Krstajic, Damjan Kumar, Luke Kurz, Christoph Kyan, Matthew Laimighofer, Michael Lee, Eunjee Lesinski, Wojciech Miaozhu Li Meier, Richard Ye Li Qiuyu Lian Xiaotao Liang Miljkovic, Dejan Mnich, Krzysztof Navab, Nassir Yu, Thomas Neto, Elias C. Newton, Yulia Pal, Subhabrata Park, Byeongju Patel, Jaykumar |
Data: | 2017 |
Editora: | Elsevier Ltd. |
Revista: | The Lancet Oncology |
Citação: | Guinney, Justin; Wang, Tao; Laajala, Teemu D.; Winner, Kimberly Kanigel; Bare, J. Christopher; Neto, Elias Chaibub; Khan, Suleiman A.; Peddinti, Gopal; Airola, Antti; Pahikkala, Tapio; Mirtti, Tuomas; Yu, Thomas; Bot, Brian M.; Shen, Liji; Abdallah, Kald; Norman, Thea; Friend, Stephen; Stolovitzky, Gustavo; Soule, Howard; Ryan, Charles J.; Scher, Howard I.; Sartor, Oliver; Xie, Yang; Tero Aittokallio; Fang Liz Zhou; James C Costello; Catalina Anghel; Helia Azima; Robert Baertsch; Pedro J Ballester; Chris Bare; Vinayak Bhandari; Cuong C Dang; Maria Bekker-Nielsen Dunbar; Ann-Sophie Buchardt; Ljubomir Buturovic; Da Cao; Prabhakar Chalise; Junwoo Cho; Tzu-Ming Chu; R Yates Coley; Sailesh Conjeti; Correia, S.; Ziwei Dai; Junqiang Dai; Philip Dargatz; Sam Delavarkhan; Detian Deng; Ankur Dhanik; Yu Du; Aparna Elangovan; Shellie Ellis; Laura L Elo; Shadrielle M Espiritu; Fan Fan; Ashkan B Farshi; Freitas, Ana Alão; Brooke Fridley; Christiane Fuchs; Eyal Gofer; Gopalacharyulu Peddinti; Stefan Graw; Russ Greiner; Yuanfang Guan; Jing Guo; Pankaj Gupta; Anna I Guyer; Jiawei Han; Niels R Hansen; Billy HW Chang; Outi Hirvonen; Barbara Huang; Chao Huang; Jinseub Hwang; Joseph G Ibrahim; Vivek Jayaswal; Jouhyun Jeon; Zhicheng Ji; Deekshith Juvvadi; Sirkku Jyrkkiö; Amin Katouzian; Marat D Kazanov; Shahin Khayyer; Dalho Kim; Agnieszka K Golinska; Devin Koestler; Pilatti, F.; Ivan Kondofersky; Norbert Krautenbacher; Damjan Krstajic; Luke Kumar; Christoph Kurz; Matthew Kyan; Michael Laimighofer; Eunjee Lee; Wojciech Lesinski; Miaozhu Li; Ye Li; Qiuyu Lian; Xiaotao Liang; Minseong Lim; Henry Lin; Xihui Lin; Jing Lu; Mehrad Mahmoudian; Roozbeh Manshaei; Richard Meier; Dejan Miljkovic; Krzysztof Mnich; Nassir Navab; Elias C Neto; Yulia Newton; Subhabrata Pal; Byeongju Park; Jaykumar Patel; Swetabh Pathak; Pattin, Alexandrina; Donna P Ankerst; Jian Peng; Anne H Petersen; Robin Philip; Stephen R Piccolo; Sebastian Pölsterl; Aneta Polewko-Klim; Karthik Rao; Xiang Ren; Rocha, Miguel; Rudnicki, Witold R.; Hyunnam Ryu; Hagen Scherb; Raghav Sehgal; Fatemeh Seyednasrollah; Jingbo Shang; Bin Shao; Howard Sher; Motoki Shiga; Artem Sokolov; Julia F Söllner; Lei Song; Josh Stuart; Ren Sun; Christopher J Sweeney; Nazanin Tahmasebi; Kar-Tong Tan; Lisbeth Tomaziu; Joseph Usset; Yeeleng S Vang; Roberto Vega; Vieira, Vítor; David Wang; Difei Wang; Junmei Wang; Lichao Wang; Sheng Wang; Yue Wang; Russ Wolfinger; Chris Wong; Zhenke Wu; Jinfeng Xiao; Xiaohui Xie; Doris Xin; Hojin Yang; Nancy Yu; Xiang Yu; Sulmaz Zahedi; Massimiliano Zanin; Chihao Zhang; Jingwen Zhang; Shihua Zhang; Yanchun Zhang; Zhu, Hongtu; Zhu, Shanfeng; Zhu, Yuxin, Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data. The Lancet Oncology, 18(1), 132-142, 2017 |
Resumo(s): | Background: Improvements to prognostic models in metastatic castration-resistant prostate cancer have the potential to augment clinical trial design and guide treatment strategies. In partnership with Project Data Sphere, a not-for-profit initiative allowing data from cancer clinical trials to be shared broadly with researchers, we designed an open-data, crowdsourced, DREAM (Dialogue for Reverse Engineering Assessments and Methods) challenge to not only identify a better prognostic model for prediction of survival in patients with metastatic castration-resistant prostate cancer but also engage a community of international data scientists to study this disease. Methods Data from the comparator arms of four phase 3 clinical trials in first-line metastatic castration-resistant prostate cancer were obtained from Project Data Sphere, comprising 476 patients treated with docetaxel and prednisone from the ASCENT2 trial, 526 patients treated with docetaxel, prednisone, and placebo in the MAINSAIL trial, 598 patients treated with docetaxel, prednisone or prednisolone, and placebo in the VENICE trial, and 470 patients treated with docetaxel and placebo in the ENTHUSE 33 trial. Datasets consisting of more than 150 clinical variables were curated centrally, including demographics, laboratory values, medical history, lesion sites, and previous treatments. Data from ASCENT2, MAINSAIL, and VENICE were released publicly to be used as training data to predict the outcome of interestnamely, overall survival. Clinical data were also released for ENTHUSE 33, but data for outcome variables (overall survival and event status) were hidden from the challenge participants so that ENTHUSE 33 could be used for independent validation. Methods were evaluated using the integrated time-dependent area under the curve (iAUC). The reference model, based on eight clinical variables and a penalised Cox proportional-hazards model, was used to compare method performance. Further validation was done using data from a fifth trialENTHUSE M1in which 266 patients with metastatic castration-resistant prostate cancer were treated with placebo alone. Findings 50 independent methods were developed to predict overall survival and were evaluated through the DREAM challenge. The top performer was based on an ensemble of penalised Cox regression models (ePCR), which uniquely identified predictive interaction effects with immune biomarkers and markers of hepatic and renal function. Overall, ePCR outperformed all other methods (iAUC 0·791; Bayes factor >5) and surpassed the reference model (iAUC 0·743; Bayes factor >20). Both the ePCR model and reference models stratified patients in the ENTHUSE 33 trial into high-risk and low-risk groups with significantly different overall survival (ePCR: hazard ratio 3·32, 95% CI 2·394·62, p<0·0001; reference model: 2·56, 1·853·53, p<0·0001). The new model was validated further on the ENTHUSE M1 cohort with similarly high performance (iAUC 0·768). Meta-analysis across all methods confirmed previously identified predictive clinical variables and revealed aspartate aminotransferase as an important, albeit previously under-reported, prognostic biomarker. Interpretation Novel prognostic factors were delineated, and the assessment of 50 methods developed by independent international teams establishes a benchmark for development of methods in the future. The results of this effort show that data-sharing, when combined with a crowdsourced challenge, is a robust and powerful framework to develop new prognostic models in advanced prostate cancer. |
Tipo: | Artigo |
URI: | https://hdl.handle.net/1822/44342 |
DOI: | 10.1016/S1470-2045(16)30560-5 |
ISSN: | 1470-2045 |
e-ISSN: | 1470-2045 |
Versão da editora: | http://www.journals.elsevier.com/the-lancet-oncology |
Arbitragem científica: | yes |
Acesso: | Acesso restrito UMinho |
Aparece nas coleções: | CEB - Publicações em Revistas/Séries Internacionais / Publications in International Journals/Series |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
document_46407_1.pdf Acesso restrito! | 1,96 MB | Adobe PDF | Ver/Abrir |